Sunpharma Ltd — Q1 FY25
Sun Pharma reported a solid Q1 FY25 with consolidated sales of INR 12,524.5 crore (+6.3% YoY) and EBITDA margin expansion of 60 bps to 28.5%.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q4 FY24
R&D spend to be 8-10% of sales in FY25
R&D investments will increase to 8-10% of sales for the next year, primarily for specialty pipeline.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q4 FY24
Deuruxolitinib launch post-PDUFA date (July 2024)
Deuruxolitinib is on track for launch after the July 2024 PDUFA date, with pre-launch costs already being incurred.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1